Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non–small-cell lung cancer in CheckMate 227

JR Brahmer, JS Lee, TE Ciuleanu… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus
ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic …
被引用次数：165 相关文章

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in …

JR Brahmer, JS Lee, TE Ciuleanu, RB Caro… - Journal of Clinical …, 2023 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> PURPOSE</jats: title>< jats: p> We present 5-year results from
CheckMate 227 Part 1, in which nivolumab plus ipilimumab improved overall survival (OS) …
[HTML] nih.gov

[HTML][HTML] Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in …

JR Brahmer, JS Lee, TE Ciuleanu… - Journal of Clinical …, 2023 - ncbi.nlm.nih.gov
PURPOSE We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus
ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic …

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in …

JR Brahmer, JS Lee, TE Ciuleanu, M Nishio… - Journal of Clinical …, 2022 - europepmc.org
Purpose We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus
ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic …

Five-Year Survival Outcomes with Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in …

JR Brahmer, JS Lee, TE Ciuleanu… - Journal of Clinical …, 2023 - eprints.qut.edu.au
PURPOSE: We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus
ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic …

[引用][C] Five-Year Survival Outcomes with Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in …

JR Brahmer, JS Lee, TE Ciuleanu… - Journal of Clinical …, 2023 - produccioncientifica.ucm.es

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in …

JR Brahmer, JS Lee, TE Ciuleanu, R Bernabe Caro… - 2023 - digital.csic.es
[Results] At a minimum follow-up of 61.3 months, 5-year OS rates were 24% versus 14% for
nivolumab plus ipilimumab versus chemotherapy (PD-L1≥ 1%) and 19% versus 7%(PD …

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in …

JR Brahmer, JS Lee, TE Ciuleanu… - Journal of Clinical …, 2023 - ingentaconnect.com
PURPOSE We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus
ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic …

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in …

JR Brahmer, JS Lee, TE Ciuleanu, RB Caro, M Nishio… - 2023 - pubmed.ncbi.nlm.nih.gov
Purpose We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus
ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic …

Five-Year Survival Outcomes with Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in …

JR Brahmer, JS Lee, TE Ciuleanu… - Journal of Clinical …, 2023 - pure.johnshopkins.edu
PURPOSEWe present 5-year results from CheckMate 227 Part 1, in which nivolumab plus
ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic …